US Edition
Trial Shows Mavacamten Benefits Adolescents with Obstructive Heart Condition
Camzyos significantly reduced heart obstruction in 44 adolescents with obstructive hypertrophic cardiomyopathy, showing improvements in cardiac structure and symptoms with a safety profile similar to placebo.
- On Sunday, March 29, 2026, Bristol Myers Squibb announced positive Phase 3 SCOUT-HCM trial data for Camzyos , marking the first study of a cardiac myosin inhibitor in adolescents aged 12 to 17 with symptomatic obstructive hypertrophic cardiomyopathy.
- Pediatric-Onset obstructive hypertrophic cardiomyopathy carries a "far worse prognosis" than adult cases, yet current guidelines rely on extrapolated adult data because no approved pediatric therapies existed previously, according to Joseph Rossano, Chief of Cardiology at Children's Hospital of Philadelphia.
- Mavacamten significantly reduced obstruction at 28 weeks, with patients experiencing a mean drop of about 48.5 mm Hg in the Valsalva LVOT gradient compared with almost no change in the placebo group.
- Data indicated a safety profile similar to adults with no new safety signals, while Rossano noted, "There's a signal that this may be favorably remodeling the heart," potentially improving the disease's natural history.
- Researchers plan to track outcomes to at least 50 weeks in the ongoing SCOUT-HCM long-term extension study, with future investigations potentially exploring efficacy in children younger than 12 years old.
25 Articles
25 Articles
Trial shows mavacamten benefits adolescents with obstructive heart condition
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
Mavacamten shows benefit for adolescents with obstructive hypertrophic cardiomyopathy
NEW ORLEANS — New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology Scientific Session.The SCOUT-HCM trial is the first to evaluate mavacamten (Camzyos, Bristol Myers Squibb) in adolescents. Mavacamten, a cardiac myosin inhibitor, is currently FDA
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
